medigraphic.com
ISSN 1405-1699 (Impreso)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2020, Número 1

<< Anterior Siguiente >>

Alerg Asma Inmunol Pediatr 2020; 29 (1)


Participantes de la respuesta inmunológica ante la infección por SARS-CoV-2

López PGT, Ramírez SMLP, Torres AMS

Idioma: Español
Referencias bibliográficas: 44
Paginas: 5-15
Archivo PDF: 401.43 Kb.


RESUMEN

Se presenta una recopilación de lo informado en la literatura sobre la respuesta inmunológica en la infección por SARS-CoV-2. Se analizan los elementos de la respuesta inmunológica no específica, la desencadenada por Linfocitos T y la mediada por anticuerpos. Se enlistan los factores de riesgo involucrados con mayor frecuencia a mala evolución y finalmente se describe brevemente las posibilidades terapéuticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abbas AK, Lichtman AH, Pillai S. In: Inmunología celular y molecular. Capítulo 1, 8ta ed. Elsevier, 2015, pp. 9-20.

  2. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al. The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19) outbreak-an update on the Status. Mil Med Res. 2020; 7: 11. https://doi.org/10.1186/s40779-020-00240-0.

  3. Letko M, Marzi A, Munster V. Functional assessmentof cell entry and receptor usage for SARS-CoV-2 andother lineage B betacoronaviruses. Nat Microbiol. 2020; 5: 562-569. doi: 10.1038/s41564-020-0688-y.

  4. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018; 14 (8): e1007236.

  5. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59: 118-128.

  6. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290: 374-380.

  7. Organización Mundial de la Salud: índice de letalidad de casos de SRAS, periodo de incubación en la URL de la World. Wide Web: http://www.who.int/csr/sarsarchive/2003_05_07a/en/.

  8. Cervantes B, Kalinke U, Kizis Z, Lopez-Macias C, Thiel BV. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009; 182: 1099-1106.

  9. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007; 81: 8692-8706.

  10. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005; 79: 155111-15524.

  11. Baas T, Taubenberger JK, Chong PY, Chui P, Katze MG. SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues. J Int Cyt Res. 2006; 26: 309-317.

  12. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007; 20 (4): 660-694.

  13. Sato K, Misawa N, Takeuchi JS, Kobayashi T, Izumi T, Aso H et al. Experimental adaptive evolution of simian immunodeficiency virus sivcpz to pandemic human immunodeficiency virus type 1 by using a humanized mouse model. J Virol. 2018; 92 (4): e01905-17.

  14. Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012; 4 (5): 833-846.

  15. Maloir Q, Ghysen K, von Frenckell C, Louis R, Guiot J. Acute respiratory distress revealing antisynthetase syndrome. Rev Med Liege. 2018; 73 (7-8): 370-375.

  16. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014; 111 (13): 4970-4975.

  17. Manni ML, Robinson KM, Alcorn JF. A tale of two cytokines: IL-17 and IL-22 in asthma and infection. Expert Rev Respir Med. 2014; 8 (1): 25-42.

  18. Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016; 34 (17): 2008-2014.

  19. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010; 84 (3): 1289-1301.

  20. Dutzan N, Abusleme L. T helper 17 cells as pathogenic drivers of periodontitis. Adv Exp Med Biol. 2019; 1197: 107-117.

  21. Yang Y, Xiong Z, Zhang S, Yan Y, Nguyen J, Ng B et al. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J. 2005; 392 (Pt 1): 135-143.

  22. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. ciaa344, https://doi.org/10.1093/cid/ciaa344.

  23. Xiao T, Gao Ch, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. Journal of Infection. 2020. doi: https://doi.org/10.1016/j.jinf.2020.03.012.

  24. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis. 2005; 11: 1730-1737.

  25. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Caracterización genómica y epidemiología del nuevo coronavirus 2019: implicaciones para los orígenes del virus y la unión al receptor. Lancet. 2020; 20: 30251-30258. pii: S0140-6736.

  26. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020; 16: 1718-1723.

  27. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38: 10-18. doi: 10.12932/AP-200220-0773.

  28. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2010; 395: 1033-1034.

  29. McGonagle D, Sharifa K, O’Regand A, Bridgewooda C. Autoimmunity reviews, y registry CCT. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). 2020. https://doi.org/10.1016/j.autrev.2020.102537.

  30. Wu D, Yang XO. Respuestas TH17 en la tormenta de citoquinas de COVID-19: Un objetivo emergente del inhibidor de JAK2 Fedratinib. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.03.005.

  31. Eakachai Prompetchara E, Ketloy E, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. doi. 10.12932/AP-200220-0772.

  32. (RITAC) Gauna M. https://fundacionio.com/wp-content/uploads/2020/04/Si%CC%81ndrome-RITAC.pdf.pdf.pdf.pdf.pdf.pdf.pdf.

  33. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020; doi: 10.1101/2020.02.06.20020974.

  34. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression procling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002; 532 (1-2): 107-110.

  35. Ling Lin, Lianfeng Lu, Wei Cao, Taisheng Li. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections. 2020; 9: 727-732. doi: 10.1080/22221751.2020.1746199.

  36. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069.

  37. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020. doi: 10.1101/2020.02.10.20021832.

  38. Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. https://doi.org/10.1148/radiol.2020201629.

  39. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18: 844-847. https://doi.org/10.1111/jth.14768.

  40. Pawelec G. Age and immunity: what is “immunosenescence”? Experimental Gerontology. 2018; 105: 4-9. doi: 10.1016/j.exger.2017.10.024.

  41. Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 2018; 28 (6): 922-934.e4. doi: 10.1016/j. cmet.2018.08.003.

  42. Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O’Toole T. Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation. Circ Res. 2016; 119 (11): 1204-1214.

  43. Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. medRxiv. 2020; doi: 10.1101/2020.02.05.20020107 (preprint).

  44. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB Pharmacologic treatments for coro navirus disease 2019 (COVID-19) a review. JAMA. Publicado en línea el 13 de abril de 2020. doi: 10.1001 / jama.2020.6019.




2020     |     www.medigraphic.com